Pharming Group Reports Strong Q1 2025 Growth

Pharming Group N.V. ( (PHGUF) ) has released its Q1 earnings. Here is a breakdown of the information Pharming Group N.V. presented to its investors.

Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for rare and life-threatening diseases, with a strong presence in over 30 markets worldwide.

In the first quarter of 2025, Pharming Group reported a significant increase in total revenues by 42% to $79.1 million, driven by strong performance in its key products, RUCONEST® and Joenja®. The company also completed the acquisition of Abliva AB, enhancing its pipeline with the KL1333 product for mitochondrial diseases.

Key financial highlights include a 49% increase in RUCONEST® revenue to $68.6 million and a 9% increase in Joenja® revenue to $10.5 million. The company reported an operating profit of $0.8 million, excluding non-recurring acquisition-related expenses, marking a turnaround from a $16.3 million loss in the previous year. Pharming also raised its 2025 revenue guidance to $325-$340 million.

Strategically, Pharming launched Joenja® in England and Wales and is preparing for a U.S. FDA filing for pediatric use. The company is advancing its clinical trials for leniolisib in primary immunodeficiencies and KL1333 in mitochondrial diseases, aiming to expand its market reach and product offerings.

Looking ahead, Pharming Group remains focused on sustainable growth through strategic capital allocation, continued patient enrollment, and regulatory advancements. The company anticipates further revenue growth and operational progress in 2025, supported by its robust pipeline and market expansion efforts.